Skip to main content
Erschienen in: World Journal of Urology 3/2012

01.06.2012 | Original Article

Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma

verfasst von: B. Amend, J. Hennenlotter, M. Scharpf, S. Kruck, U. Kuehs, E. Senger, A. S. Merseburger, M. A. Kuczyk, K. D. Sievert, A. Stenzl, J. Bedke

Erschienen in: World Journal of Urology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Renal oncocytomas are assigned as benign tumours, and their detailed molecular mechanism is poorly characterised. Activation of the PKB/Akt pathway is assumed to contribute to the pathogenesis and progression of malignant disease. For oncocytomas, hardly any data are available for Akt signalling parameters. Aim of the present work was to determine the alterations of Akt parameters PTEN, phosphorylated Akt (p-Akt) and p27Kip1 in oncocytoma to better understand the dedifferentiation of renal tumours.

Methods

By tissue microarray analysis 15 oncocytoma, 18 clear cell renal cell carcinoma (ccRCC) and the corresponding benign tissue were investigated. Significant expression differences between PTEN, p-Akt and p27Kip1 were determined by immunohistochemistry using One-way ANOVA with all pairs Tukey–Kramer as post hoc analyses. To investigate Akt parameter interactions in the oncocytoma, linear regression analyses were performed.

Results

Expression of all proteins was significantly different between the groups and in all groups the lowest for oncocytoma: PTEN: 32.9 ± 13.0 versus 75.5 ± 8.0 versus 123.7 ± 8.8; p < 0.001 for oncocytoma, benign parenchyma and ccRCC and 2.7 ± 1.2 versus 40.8 ± 9.5 versus 143.6 ± 12.2; p < 0.001 for p27Kip1. p-Akt expression was significantly different between oncocytoma and ccRCC (67.3 ± 15.7 vs. 144.0 ± 26.6; p < 0.05).

Conclusion

All three investigated parameters were the lowest in oncocytoma when compared to ccRCC. Expression of PTEN and p27Kip1 seems to be exceedingly associated with malignant conditions of ccRCC. These findings might contribute to the understanding of tumorous signalling of the PKB/Akt axis in renal tumours.
Literatur
1.
Zurück zum Zitat Romis L et al (2004) Frequency, clinical presentation and evolution of renal oncocytomas: multicentric experience from a European database. Eur Urol 45:53–57 (discussion 57)PubMedCrossRef Romis L et al (2004) Frequency, clinical presentation and evolution of renal oncocytomas: multicentric experience from a European database. Eur Urol 45:53–57 (discussion 57)PubMedCrossRef
2.
Zurück zum Zitat Eble JN (2004) Tumors at the kidney, chap 1. In: Eble JN, Sauter G, Epstein JI (eds) Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organisation classification of tumours. IARC Press, Lyons, pp 9–88 Eble JN (2004) Tumors at the kidney, chap 1. In: Eble JN, Sauter G, Epstein JI (eds) Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organisation classification of tumours. IARC Press, Lyons, pp 9–88
3.
Zurück zum Zitat Van der Kwast T, Perez-Ordonez B (2007) Renal oncocytoma, yet another tumour that does not fit in the dualistic benign/malignant paradigm? J Clin Pathol 60:585–586PubMedCrossRef Van der Kwast T, Perez-Ordonez B (2007) Renal oncocytoma, yet another tumour that does not fit in the dualistic benign/malignant paradigm? J Clin Pathol 60:585–586PubMedCrossRef
4.
Zurück zum Zitat Gudbjartsson T et al (2005) Renal oncocytoma: a clinicopathological analysis of 45 consecutive cases. BJU Int 96:1275–1279PubMedCrossRef Gudbjartsson T et al (2005) Renal oncocytoma: a clinicopathological analysis of 45 consecutive cases. BJU Int 96:1275–1279PubMedCrossRef
5.
Zurück zum Zitat Cheng L et al (2009) Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol 40:10–29PubMedCrossRef Cheng L et al (2009) Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol 40:10–29PubMedCrossRef
6.
Zurück zum Zitat Cossu-Rocca P et al (2008) Interphase cytogenetic analysis with centromeric probes for chromosomes 1, 2, 6, 10, and 17 in 11 tumors from a patient with bilateral renal oncocytosis. Mod Pathol 21:498–504PubMedCrossRef Cossu-Rocca P et al (2008) Interphase cytogenetic analysis with centromeric probes for chromosomes 1, 2, 6, 10, and 17 in 11 tumors from a patient with bilateral renal oncocytosis. Mod Pathol 21:498–504PubMedCrossRef
7.
Zurück zum Zitat Fuzesi L et al (1994) Renal oncocytoma with a translocation t(9;11) (p23;q13). J Urol 152:471–472PubMed Fuzesi L et al (1994) Renal oncocytoma with a translocation t(9;11) (p23;q13). J Urol 152:471–472PubMed
8.
Zurück zum Zitat Rohan S et al (2006) Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clin Cancer Res 12:6937–6945PubMedCrossRef Rohan S et al (2006) Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clin Cancer Res 12:6937–6945PubMedCrossRef
9.
Zurück zum Zitat Escudier B et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef Escudier B et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef
10.
Zurück zum Zitat Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef
11.
Zurück zum Zitat Song G, Ouyang G, Bao S (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9:59–71PubMedCrossRef Song G, Ouyang G, Bao S (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9:59–71PubMedCrossRef
12.
Zurück zum Zitat Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455–7464PubMedCrossRef Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455–7464PubMedCrossRef
13.
Zurück zum Zitat Samuels Y, Ericson K (2006) Oncogenic PI3 K and its role in cancer. Curr Opin Oncol 18:77–82PubMedCrossRef Samuels Y, Ericson K (2006) Oncogenic PI3 K and its role in cancer. Curr Opin Oncol 18:77–82PubMedCrossRef
14.
Zurück zum Zitat Brenner W et al (2002) Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 99:53–57PubMedCrossRef Brenner W et al (2002) Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 99:53–57PubMedCrossRef
15.
Zurück zum Zitat Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663PubMedCrossRef Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663PubMedCrossRef
16.
Zurück zum Zitat Merseburger AS et al (2006) Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep 16:79–83PubMed Merseburger AS et al (2006) Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep 16:79–83PubMed
17.
Zurück zum Zitat Merseburger AS et al (2005) Cathepsin D expression in renal cell cancer-clinical implications. Eur Urol 48:519–526PubMedCrossRef Merseburger AS et al (2005) Cathepsin D expression in renal cell cancer-clinical implications. Eur Urol 48:519–526PubMedCrossRef
18.
Zurück zum Zitat Pantuck AJ et al (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109:2257–2267PubMedCrossRef Pantuck AJ et al (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109:2257–2267PubMedCrossRef
19.
Zurück zum Zitat Downes CP et al (2001) Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN. Biochem Soc Trans 29:846–851PubMedCrossRef Downes CP et al (2001) Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN. Biochem Soc Trans 29:846–851PubMedCrossRef
20.
Zurück zum Zitat Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240–4245PubMedCrossRef Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240–4245PubMedCrossRef
21.
Zurück zum Zitat Vazquez F, Sellers WR (2000) The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 1470:M21–M35PubMed Vazquez F, Sellers WR (2000) The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 1470:M21–M35PubMed
22.
Zurück zum Zitat Slingerland J, Pagano M (2000) Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183:10–17PubMedCrossRef Slingerland J, Pagano M (2000) Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183:10–17PubMedCrossRef
23.
Zurück zum Zitat Hennenlotter J et al (2008) PTEN and p27Kip1 are not downregulated in the majority of renal cell carcinomas-implications for Akt activation. Oncol Rep 19:1141–1147PubMed Hennenlotter J et al (2008) PTEN and p27Kip1 are not downregulated in the majority of renal cell carcinomas-implications for Akt activation. Oncol Rep 19:1141–1147PubMed
25.
Zurück zum Zitat Guijarro MV et al (2007) MAP17 inhibits Myc-induced apoptosis through PI3 K/AKT pathway activation. Carcinogenesis 28:2443–2450PubMedCrossRef Guijarro MV et al (2007) MAP17 inhibits Myc-induced apoptosis through PI3 K/AKT pathway activation. Carcinogenesis 28:2443–2450PubMedCrossRef
26.
Zurück zum Zitat Ignatoski KMW et al (2003) The role of phosphatidylinositol 3′-kinase and its downstream signals in erbB-2-mediated transformation. Mol Cancer Res 1:551–560 Ignatoski KMW et al (2003) The role of phosphatidylinositol 3′-kinase and its downstream signals in erbB-2-mediated transformation. Mol Cancer Res 1:551–560
27.
Zurück zum Zitat Kruck S et al (2011) High cytoplasmic expression of p27Kip1 is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int (in press) Kruck S et al (2011) High cytoplasmic expression of p27Kip1 is associated with a worse cancer-specific survival in clear cell renal cell carcinoma. BJU Int (in press)
28.
Zurück zum Zitat Viglietto G, Motti ML, Fusco A (2002) Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. Cell Cycle 1:394–400PubMedCrossRef Viglietto G, Motti ML, Fusco A (2002) Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. Cell Cycle 1:394–400PubMedCrossRef
Metadaten
Titel
Akt signalling parameters are different in oncocytomas compared to renal cell carcinoma
verfasst von
B. Amend
J. Hennenlotter
M. Scharpf
S. Kruck
U. Kuehs
E. Senger
A. S. Merseburger
M. A. Kuczyk
K. D. Sievert
A. Stenzl
J. Bedke
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 3/2012
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-011-0737-5

Weitere Artikel der Ausgabe 3/2012

World Journal of Urology 3/2012 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.